Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells

Hypertension

Volumn 60, Issue 3, 2012, Pages 757-764

  Jackson, Edwin K ^a   Kochanek, Stanton J ^a   Gillespie, Delbert G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

cell proliferation; dipeptidyl peptidase IV; mesangial cells; neuropeptide Y 1 36; peptide YY1 36; preglomerular vascular smooth muscle cells; spontaneously hypertensive rats

Indexed keywords

COLLAGEN; DIPEPTIDYL PEPTIDASE IV; MESSENGER RNA; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; PROLINE; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTRANSFORMATION; CELL PROLIFERATION; CELL TYPE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; GLOMERULUS; HYPERTENSION; KIDNEY DYSFUNCTION; MESANGIUM CELL; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; ARGININE; CELL PROLIFERATION; CELLS, CULTURED; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR MESANGIUM; GLUCAGON-LIKE PEPTIDE 1; MALE; MODELS, ANIMAL; MUSCLE, SMOOTH, VASCULAR; NEUROPEPTIDE Y; PEPTIDE YY; PROLINE; PYRAZINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; THYMIDINE; TRIAZOLES;

EID: 84865447930     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.196501     Document Type: Article

References (25)

1. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454-1470.
2. Reynolds K, Wildman RP. Update on the metabolic syndrome: hypertension. Curr Hypertens Rep. 2009;11:150-155.
3. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128:159-165.
4. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005;108:277-292.
5. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.
6. Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54:516-523.
7. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med. 2003;228:217-244.
8. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77:75-197.
9. Haefliger JA, Waeber B, Grouzmann E, Braissant O, Nussberger J, Nicod P, Waeber G. Cellular localization, expression and regulation of neuropeptide Y in kidneys of hypertensive rats. Regul Pept. 1999;82:35-43.
10. Anini Y, Fu-Cheng X, Cuber JC, Kervran A, Chariot J, Roz C. Comparison of the postprandial release of peptide YY and proglucagonderived peptides in the rat. Pflugers Arch. 1999;438:299-306.
11. Fu-Cheng X, Anini Y, Chariot J, Castex N, Galmiche JP, Roze C. Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch. 1997;433: 571-579.
12. Esler M, Rumantir M, Wiesner G, Kaye D, Hastings J, Lambert G. Sympathetic nervous system and insulin resistance: from obesity to diabetes. Am J Hypertens. 2001;14:304S-309S.
13. Freire RD, Cardoso MA, Gimeno SGA, Ferreira SRG, Japanese-Brazilian Diabetes Study G. Dietary fat is associated with metabolic syndrome in Japanese Brazilians. Diabetes Care. 2005;28:1779-1785.
14. Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998;50:143-150.
15. Bauvois B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem J. 1988;252: 723-731.
16. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptordependent and-independent pathways. Circulation. 2008;117: 2340-2350. (Correction. 2008;118:e81.)
17. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008;478:136-142.
18. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens. 1997;6: 88-105.
19. Pons J, Kitlinska J, Jacques D, Perreault C, Nader M, Everhart L, Zhang Y, Zukowska Z. Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Can J Physiol Pharmacol. 2008;86:438-448.
20. Dubinion JH, Mi Z, Zhu C, Gao L, Jackson EK. Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction. Hypertension. 2006;47:545-551.
21. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23: 479-486.
22. Li XC, Carretero OA, Shao Y, Zhuo JL. Glucagon receptor-mediated extracellular signal-regulated kinase 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hypertension. 2006;47: 580-585.
23. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP IV) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocininduced model using wild-type and DPP IV-deficient rats. J Endocrinol. 2008:JOE-08-0424.
24. Lestner JM, Baburaj R, Edwards CMB. Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity? Br J Hosp Med. 2011;72:412-413.
25. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56:728-733.